Sarepta Therapeutics (NASDAQ:SRPT) Given New $25.00 Price Target at Deutsche Bank Aktiengesellschaft

Sarepta Therapeutics (NASDAQ:SRPT) had its target price trimmed by Deutsche Bank Aktiengesellschaft from $50.00 to $25.00 in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a hold rating on the biotechnology company’s stock.

A number of other analysts have also recently issued reports on SRPT. Needham & Company LLC lowered their target price on Sarepta Therapeutics from $125.00 to $50.00 and set a “buy” rating for the company in a research note on Monday. Barclays lowered their price objective on shares of Sarepta Therapeutics from $89.00 to $29.00 and set an “overweight” rating for the company in a research report on Tuesday. Royal Bank Of Canada cut their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a research report on Wednesday, May 7th. Guggenheim decreased their price target on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Finally, Evercore ISI downgraded Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 target price on the stock. in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $74.13.

Sarepta Therapeutics Trading Up 3.0%

Shares of NASDAQ SRPT opened at $21.56 on Tuesday. Sarepta Therapeutics has a twelve month low of $18.30 and a twelve month high of $173.25. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -8.01 and a beta of 0.61. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The company’s fifty day moving average is $45.00 and its 200-day moving average is $84.80.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). The business had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The firm’s revenue was up 80.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.73 earnings per share. Equities research analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SRPT. Steward Partners Investment Advisory LLC lifted its holdings in Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 194 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after buying an additional 216 shares in the last quarter. Byrne Asset Management LLC bought a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $30,000. Center for Financial Planning Inc. acquired a new position in shares of Sarepta Therapeutics in the first quarter valued at about $31,000. Finally, Logan Capital Management Inc. bought a new position in Sarepta Therapeutics during the fourth quarter worth about $61,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.